CIBINQO® Launch

CIBINQO^®  (abrocitinib) is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

This site launched during COVID. I helped build the site from start to finish using the Pfizer Helix design system. Answered many questions from staff about how the design system worked and how we would stay within its parameters. Collaborated with Art and Dev teamd on building the skin tool and many efficacy charts. Live site available athttps://cibinqo.pfizerpro.com/.